
November 2026
Vitrafy Life Sciences Ltd is the research, development and commercialisation of its integrated cryopreservation solution. This includes cryopreservation medical devices (freezer, thawer and packaging solutions), Life Chain integrated software system, and services for application areas in human health and animal reproduction. The group has one operating segment. The company's solutions are LifeChain TM, and Guardion TM. LifeChain TM is the nexus of modern cryopreservation, an intelligent platform unifying data-driven optimization, world-wide logistics, and proprietary algorithms to create bespoke freeze curves. Guardion TM rapidly freezes T-cells in under four minutes while maintaining post-thaw quality rivaling fresh controls. | $2 | +83% | $136M | $109M | 955.3x | (9.6x) | |||
AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its key areas are the Energy and Life Science Division. The company is developing four products named AnteoX, Ultranode, AnteoBind NXT, and AnteoBind these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the AnteoTech IP. | $0 | -11% | $35M | $29M | 92.4x | (10.4x) | |||
Microba Life Sciences is an Australian precision microbiome company based in Brisbane that sells clinical gut microbiome tests and supplements and holds a pipeline of microbiome-based therapeutic candidates. It was founded in 2017 as a University of Queensland spin-out by Professors Gene Tyson and Philip Hugenholtz and listed on the Australian Securities Exchange on 5 April 2022. Its main product, MetaXplore, is a gastrointestinal test sold to clinicians in Australia and the United Kingdom, where it bought the Invivo Healthcare testing and supplements business in December 2023. Group revenue was A$15.7 million in the year to June 2025, up 30 per cent, and the net loss was A$14.9 million. Sonic Healthcare is its largest shareholder and a distribution partner for its tests. Microba transferred its research services unit to Clinical Microbiomics in late 2024 and paused internal research and development in the 2025 financial year to look for partners for its therapeutic assets. In 2026 it agreed commercial terms for a proposed all-scrip merger with Genetic Signatures. | $0 | -50% | $18M | $15M | 1.6x | (1.4x) | |||
Pathkey.AI Ltd is engaged in the development of its digital tools that improve clinical trials, healthcare experience for patients, deliver deep market insights from social media data, and improve the efficiency and value of the clinical research process. It invests in research and develops technologies as well as provides digital tools and insights services to healthcare, wellness, and science technology-focused clients. The group's main revenue streams are Retainer revenue and Project revenue. | $0 | -11% | $12M | $10M | 311.8x | (3.9x) | |||
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx. | $0 | -75% | $11M | $8M | 44.8x | (1.6x) | |||
| Median | $0 | -11% | $18M | $15M | 92.4x | (3.9x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.